•
Sep 6, 2024
Sep 5, 2024
Aug 14, 2024
Aug 13, 2024
Aug 8, 2024
Aug 29, 2024
Aug 26, 2024
Sep 4, 2024
Aug 28, 2024
Aug 9, 2024
Xencor Inc [XNCR] has reported fiscal Q1 loss of $60.70 million.
On a per-share basis, the DE based company said its diluted earnings are $1.02.
The Pharmaceutical Preparations firm posted revenue of $18.90 million in this period.
Also Read: Xencor to Host First Quarter 2023 Financial Results Webcast and Conference Call on May 8, 2023Xencor Appoints Nancy Valente, M.D., as Chief Development OfficerXencor Highlights CD28 Bispecific Antibody Platform at AACR Annual Meeting 2023Xencor Presents Data from Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin Lymphoma at the American Society of Hematology Annual Meeting